Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4897144 | 0.91 | NOS2 (0.73) | NOS2NOS1 | |
| SCHEMBL3568767 | 0.88 | NOS2 (0.74) | NOS2NOS1 | |
| SCHEMBL14034519 | 0.87 | NOS2 (0.74) | NOS2NOS1 | |
| SCHEMBL3562711 | 0.86 | NOS2 (0.71) | NOS2NOS1 | |
| SCHEMBL4888876 | 0.83 | NOS2 (0.72) | NOS2NOS1 | |
| SCHEMBL3565871 | 0.83 | NOS2 (0.57) | NOS2NOS1 | |
| SCHEMBL4888882 | 0.81 | NOS2 (1.00) | NOS2NOS1 | |
| SCHEMBL3566884 | 0.80 | NOS2 (0.68) | NOS2NOS1 | |
| SCHEMBL3564686 | 0.79 | NOS2 (0.52) | NOS2NOS1 | |
| SCHEMBL3567452 | 0.79 | NOS2 (0.55) | NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080293942-A1 | Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives | COUSINS RUSSELL D | 2008-11-27 | — | — | US | disclosed |
| US-20080293942-A1 | Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives | COUSINS RUSSELL D | 2008-11-27 | — | — | US | disclosed |
| WO-2007062417-A1 | METHODS OF PREPARING 2-IMIDAZOL-1-YL-4-METHYL-6-PYRROLIDIN-2-YL-PYRIMIDINE AND 4-(1-ALKYLPYRROLIDIN-2-YL)-2-(1H-IMIDAZOL-1-YL)-6-METHYLPYRIMIDINE DERIVATIVES | KALYPSYS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293942-A1 | Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives | NOS2, NOS1, NOS3 | NOS2 1/4885NOS1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.